

Management of Atrial Fibrillation



Heart Rhythm Society

Restoring the Rhythm of Life

Program Overview

Atrial fibrillation (AF) is one of the most common cardiac arrhythmias, yet its treatment remains inadequate for many patients. This activity will cover the merits of catheter ablation versus drug therapy for maintenance of sinus rhythm, as well as pharmacological conversion versus use of a device for acute defibrillation. New therapeutic approaches, currently in clinical development for AF cardioversion, will also be covered.



Heart Rhythm Society
Restoring the Rhythm of Life

Target Audience

This activity is intended for physicians and other healthcare community members providing clinical care to patients.



Heart Rhythm Society
Restoring the Rhythm of Life

Learning Objectives

Upon completion of this activity, participants should be able to:

- Review the prevalence and current clinical management of AF
- Understand new nonpharmacologic and pharmacologic anti-arrhythmic therapies being developed for cardioversion of AF
- Analyze clinical trial evidence and understand the efficacy and safety of new antiarrhythmic therapies
- Know the benefits of nonpharmacologic versus pharmacologic treatments for AF and their integration into clinical practice



Heart Rhythm Society
Restoring the Rhythm of Life

Accreditation Statement

Heart Rhythm Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

Heart Rhythm Society designates this education activity for a maximum of 2.5 category 1 credits toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.



Heart Rhythm Society
Restoring the Rhythm of Life

Instructions for credit

Participation in this self-study activity should be completed in approximately 2.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from September, 2005 through September 2007.

1. Read the target audience, learning objectives and faculty disclosures
2. Study the educational activity.
3. Submit answers to the post-test questions and evaluation.

You must complete the post-test and respond to the evaluation questions to receive a certificate.



Heart Rhythm Society
Restoring the Rhythm of Life

Disclosures

Conflicts of Interest/Unlabeled/Unapproved Uses

The Heart Rhythm Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. As a provider of continuing medical education, it is the Society's policy to ensure that the contents or formats of a continuing medical education (CME) activity are balanced, independent, objective, scientifically rigorous and free of commercial bias in all of its educational activities. It is the policy of HRS that all faculty participating in continuing medical education activities are expected to disclose to the program audience (1) any real or apparent conflict(s) or interest related to the content of their presentation and (2) discussions of unlabeled or unapproved uses of drugs or medical devices.



Heart Rhythm Society

Restoring the Rhythm of Life

Faculty Disclosures

- **Camm, John A.:** has disclosed that he has served as a consultant/advisor to: Sanofi Aventis, Procter and Gamble; Wyeth, Cardiome, Xention, Astra-Zeneca, Servier, CVT, GlaxoSmithKline, Bayer, Abbot, Pfizer, Johnson and Johnson, Wyeth, Vitatron, St. Jude Medical and Guidant. He has received research support from Pfizer, Solvay and Servier and he has served on the speaker's bureau: for Cardiome/Astellas, Sanofi-Aventis, Servier, and Medtronic.
- **Dorian, Paul:** has disclosed that he has been a consultant to and has received research funding from Cardiome Pharma Corp., Solvay Pharmaceuticals, Sanofi-Synthelabo Canada Inc., Procter & Gamble Pharmaceuticals, and AstraZeneca.
- **Kowey, Peter:** has consulted for, delivered lectures sponsored by, and has been the recipient of grants from several pharmaceutical and device companies including but not limited to: Abbott, Alteon, Astra-Zeneca, Berlex, Cardiome, CVT, Forest, GlaxoSmithKline, Guidant, Johnson & Johnson, Medifacts, Medtronic, Merck, Novartis, Pfizer, Procter & Gamble, Reliant, Sanofi-Aventis, Solvay, and Wyeth. He also owns equity interest in Cardionet.
- **Mitchell, Brent L:** has nothing to disclose.



Heart Rhythm Society
Restoring the Rhythm of Life

Disclaimer

The materials published on the website reflect the views of the authors, not those of the Heart Rhythm Society, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using therapies described in these materials.